| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Over the last 12 months, insiders at NanoViricides, Inc. have bought $0 and sold $0 worth of NanoViricides, Inc. stock.
On average, over the past 5 years, insiders at NanoViricides, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $30,000 was made by BONIUK MILTON (director) on 2015‑11‑11.
| 2015-11-11 | BONIUK MILTON | director | 25,000 0.0431% | $1.20 | $30,000 | +33.88% | ||
| 2015-10-22 | BONIUK MILTON | director | 14,640 0.0254% | $1.30 | $19,032 | +24.62% | ||
| 2015-10-21 | BONIUK MILTON | director | 5,202 0.009% | $1.30 | $6,763 | +24.62% | ||
| 2015-10-19 | BONIUK MILTON | director | 2,958 0.0051% | $1.30 | $3,845 | +22.73% | ||
| 2015-10-15 | BONIUK MILTON | director | 2,200 0.0037% | $1.30 | $2,860 | +20.00% | ||
| 2015-09-11 | BONIUK MILTON | director | 50,000 0.0873% | $1.02 | $51,000 | +53.92% | ||
| 2015-08-26 | BONIUK MILTON | director | 50,000 0.0921% | $1.05 | $52,500 | +55.65% | ||
| 2015-08-21 | BONIUK MILTON | director | 29,853 0.053% | $1.25 | $37,316 | +26.02% | ||
| 2015-08-20 | BONIUK MILTON | director | 2,662 0.0046% | $1.25 | $3,328 | +24.00% | ||
| 2015-08-19 | BONIUK MILTON | director | 300 0.0005% | $1.25 | $375 | +20.16% | ||
| 2015-08-18 | BONIUK MILTON | director | 2,547 0.0043% | $1.25 | $3,184 | +20.16% | ||
| 2015-08-17 | BONIUK MILTON | director | 5,244 0.0092% | $1.25 | $6,555 | +24.00% | ||
| 2015-08-14 | BONIUK MILTON | director | 8,594 0.0148% | $1.25 | $10,743 | +20.47% | ||
| 2015-08-13 | BONIUK MILTON | director | 800 0.0013% | $1.25 | $1,000 | +14.18% | ||
| 2015-07-08 | BONIUK MILTON | director | 50,000 0.092% | $1.58 | $79,000 | -6.00% | ||
| 2015-06-22 | BONIUK MILTON | director | 43,472 0.074% | $1.90 | $82,597 | -27.69% | ||
| 2015-06-19 | BONIUK MILTON | director | 6,528 0.0113% | $1.90 | $12,403 | -27.08% | ||
| 2015-06-16 | BONIUK MILTON | director | 42,247 0.0738% | $1.99 | $84,072 | -29.15% | ||
| 2015-06-15 | BONIUK MILTON | director | 7,753 0.0135% | $2.00 | $15,506 | -29.50% | ||
| 2015-05-20 | BONIUK MILTON | director | 25,000 0.0431% | $1.60 | $40,000 | -12.96% |
| Theracour Pharma, Inc. | 10 percent owner | 33321000 207.3233% | $55.98M | 0 | 86 | |
| Seymour Eugene | Chief Executive Officer | 6025000 37.4876% | $10.12M | 1 | 0 | +75.74% |
| Diwan Anil | President | 2074918 12.9101% | $3.49M | 9 | 75 | +24.68% |
| BONIUK MILTON | director | 150000 0.9333% | $252,000.00 | 35 | 0 | <0.0001% |
| VYAS MEETA | Chief Financial Officer | 147021 0.9148% | $246,995.28 | 1 | 0 | <0.0001% |
$155,580,641 | 77 | -24.21% | $23.91M | |
$17,268,389 | 57 | -18.16% | $25.73M | |
NanoViricides, Inc. (NNVC) | $6,204,522 | 45 | 1.91% | $27M |
$395,438 | 43 | -21.25% | $22.47M | |
$22,323,743 | 39 | 23.92% | $31.78M | |
$1,995,470 | 22 | 14.01% | $22.81M | |
$36,557,692 | 17 | 3.38% | $33.19M | |
$20,234,041 | 17 | 2.09% | $33.26M | |
$139,007,129 | 16 | 47.16% | $27.24M | |
$156,484,110 | 12 | 52.55% | $27.07M | |
$19,300,035 | 11 | 45.88% | $31.78M | |
$189,648 | 9 | -52.20% | $23.88M | |
$1,472,879 | 6 | -13.59% | $30.92M | |
$147,504 | 5 | -36.70% | $22.2M | |
$26,000,000 | 5 | -56.00% | $22.21M | |
$1,184,658 | 4 | -22.17% | $22.68M | |
$157,740 | 3 | 153.95% | $27.14M | |
$100,266 | 2 | 3.17% | $29.3M | |
$500,000 | 1 | -22.94% | $22.3M |
| Increased Positions | 9 | +23.08% | 119,376 | +8.05% |
| Decreased Positions | 8 | -20.51% | 136,521 | -9.2% |
| New Positions | 3 | New | 53,778 | New |
| Sold Out Positions | 3 | Sold Out | 44,476 | Sold Out |
| Total Postitions | 40 | +2.56% | 1M | -1.16% |
| Vanguard Group Inc | $664.00 | 3.19% | 510,416 | 0 | 0% | 2024-12-31 |
| Compagnie Lombard Odier Scma | $260.00 | 1.25% | 200,000 | +50,000 | +33.33% | 2025-03-31 |
| Blackrock, Inc. | $206.00 | 0.99% | 158,752 | 0 | 0% | 2025-03-31 |
| Renaissance Technologies Llc | $189.00 | 0.91% | 145,700 | +30,800 | +26.81% | 2024-12-31 |
| Geode Capital Management, Llc | $186.00 | 0.9% | 143,313 | +31,956 | +28.7% | 2024-12-31 |
| Virtu Financial Llc | $83.00 | 0.4% | 63,644 | +63,644 | New | 2024-12-31 |
| Bridgeway Capital Management, Llc | $57.00 | 0.28% | 44,039 | 0 | 0% | 2024-12-31 |
| State Street Corp | $54.00 | 0.26% | 41,906 | 0 | 0% | 2024-12-31 |
| Integrated Wealth Concepts Llc | $49.00 | 0.24% | 38,035 | -15,300 | -28.69% | 2024-12-31 |
| Royal Bank Of Canada | $40.00 | 0.19% | 30,535 | 0 | 0% | 2024-12-31 |